Huxley Health finalizes Sintalica deal, names Bruce Linton chairman

The company also named several other new executives.

Privately owned psychedelics company Huxley Health Inc. completed its acquisition of Canadian drug discovery company Sintalica and named Bruce Linton as its new chairman.

Sintalica operates through its Italian subsidiary and is focused on using psychedelics to create treatments for neuroinflammatory disorders. Sintalica filed four provisional patents for proprietary psychedelic molecules with unique properties, improved stability and safety profiles, and enhanced bioavailability. The deal was an all-stock transaction valued at $7.2 million.

Former Canopy Growth founder and CEO Bruce Linton was named as the company’s new chairman, replacing Michael Marchese, who previously served as the company’s only director. Linton is also chair of the advisory board of Red Light Holland Corp. (CSE: TRIP).

New team

The company continued to beef up its board and C-suite with an all-male team featuring new board members Fabian Monaco, who was also the co-founder and former CEO of Gage Growth Corp., which was acquired by TerrAscend Corp. (TSX: TSND) (OTCQX: TSNDF), and investor John Di Girolamo.

Huxley named Jared Rhines as its new chief executive officer. Rhines’ experience spans clinical research, regulatory affairs, sales, marketing, and market access in multiple therapeutic areas, including rare diseases, neurology, cardiology, and critical care. He, along with five colleagues, founded INO Therapeutics, a company that was eventually acquired for $2.3 billion.

The new chief science officer is George Jackowski, who has experience clearing 25 products through the FDA and commercializing them globally, with revenues exceeding $10 billion. He holds more than 200 issued patents.

Peter Kampian was named the chief financial officer.

Together Huxley and Sintalica have raised $6 million. The company has also successfully filed more than 10 U.S. patents to protect its intellectual property portfolio, including candidates undergoing pre-clinical testing.

Debra Borchardt

Debra Borchardt is the Co-Founder, and Executive Editor of GMR. She has covered the cannabis industry for several years at Forbes, Seeking Alpha and TheStreet. Prior to becoming a financial journalist, Debra was a Vice President at Bear Stearns where she held a Series 7 and Registered Investment Advisor license. Debra has a Master's degree in Business Journalism from New York University.


One comment

  • Roger M

    February 16, 2024 at 10:18 pm

    This sleepy deal came out of nowhere…

    Since this somewhat ambiguous NR I’ve heard the name mentioned in Vancouver and was asked about it from Toronto contacts. (I’ve invested in multiple psych deals early on)

    I reached out to the company and will report back if I can learn more .

    Do they have plans of going public? I wonder if this could be the beginnings of something big or they’re keeping it private on purpose?

    Let us know if you can find out more !

    Reply

Leave a Reply

Your email address will not be published. Required fields are marked *

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.

 Sign up


About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.